{"id":"https://openalex.org/W3083367621","doi":"https://doi.org/10.6004/jnccn.2020.7640","title":"Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy","display_name":"Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy","publication_year":2020,"publication_date":"2020-09-01","ids":{"openalex":"https://openalex.org/W3083367621","doi":"https://doi.org/10.6004/jnccn.2020.7640","mag":"3083367621","pmid":"https://pubmed.ncbi.nlm.nih.gov/32886906"},"language":"en","primary_location":{"id":"doi:10.6004/jnccn.2020.7640","doi":"https://doi.org/10.6004/jnccn.2020.7640","is_oa":true,"landing_page_url":"https://doi.org/10.6004/jnccn.2020.7640","pdf_url":"https://jnccn.org/downloadpdf/journals/jnccn/18/9/article-p1287.pdf","source":{"id":"https://openalex.org/S935620192","display_name":"Journal of the National Comprehensive Cancer Network","issn_l":"1540-1405","issn":["1540-1405","1540-1413"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4324004213","host_organization_name":"National Comprehensive Cancer","host_organization_lineage":["https://openalex.org/P4324004213"],"host_organization_lineage_names":["National Comprehensive Cancer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the National Comprehensive Cancer Network","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://jnccn.org/downloadpdf/journals/jnccn/18/9/article-p1287.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041881080","display_name":"Nanruoyi Zhou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I2799798094","display_name":"UCLA Health","ror":"https://ror.org/01d88se56","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nanruoyi Zhou","raw_affiliation_strings":["Geffen School of Medicine at UCLA","2020 Santa Monica Boulevard, Suite 600, Santa Monica, CA 90404","Hematology-Oncology Fellow at the David Geffen School of Medicine at UCLA","Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"2020 Santa Monica Boulevard, Suite 600, Santa Monica, CA 90404","institution_ids":[]},{"raw_affiliation_string":"Hematology-Oncology Fellow at the David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"Medicine at UCLA","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I2799798094"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059052850","display_name":"Maria A. Velez","orcid":"https://orcid.org/0000-0001-5197-4719","observed_orcids":["https://orcid.org/0000-0001-5197-4719"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I2799798094","display_name":"UCLA Health","ror":"https://ror.org/01d88se56","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria A. Velez","raw_affiliation_strings":["Geffen School of Medicine at UCLA","2020 Santa Monica Boulevard, Suite 600, Santa Monica, CA 90404","Hematology-Oncology Fellow at the David Geffen School of Medicine at UCLA","Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"2020 Santa Monica Boulevard, Suite 600, Santa Monica, CA 90404","institution_ids":[]},{"raw_affiliation_string":"Hematology-Oncology Fellow at the David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"Medicine at UCLA","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I2799798094"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091280788","display_name":"Dwight Hall Owen","orcid":"https://orcid.org/0000-0002-6598-4886","observed_orcids":["https://orcid.org/0000-0002-6598-4886"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I2799798094","display_name":"UCLA Health","ror":"https://ror.org/01d88se56","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dwight Owen","raw_affiliation_strings":["Geffen School of Medicine at UCLA","2020 Santa Monica Boulevard, Suite 600, Santa Monica, CA 90404","Hematology-Oncology Fellow at the David Geffen School of Medicine at UCLA","Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"2020 Santa Monica Boulevard, Suite 600, Santa Monica, CA 90404","institution_ids":[]},{"raw_affiliation_string":"Hematology-Oncology Fellow at the David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"Medicine at UCLA","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I2799798094"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078435189","display_name":"Aaron Elliott Lisberg","orcid":"https://orcid.org/0000-0003-3048-4352","observed_orcids":["https://orcid.org/0000-0003-3048-4352"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I2799798094","display_name":"UCLA Health","ror":"https://ror.org/01d88se56","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Aaron E. Lisberg","raw_affiliation_strings":["Geffen School of Medicine at UCLA","2020 Santa Monica Boulevard, Suite 600, Santa Monica, CA 90404","Hematology-Oncology Fellow at the David Geffen School of Medicine at UCLA","Medicine at UCLA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"2020 Santa Monica Boulevard, Suite 600, Santa Monica, CA 90404","institution_ids":[]},{"raw_affiliation_string":"Hematology-Oncology Fellow at the David Geffen School of Medicine at UCLA","institution_ids":["https://openalex.org/I161318765"]},{"raw_affiliation_string":"Medicine at UCLA","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I2799798094"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5078435189"],"corresponding_institution_ids":["https://openalex.org/I161318765","https://openalex.org/I2799798094"],"apc_list":null,"apc_paid":null,"fwci":0.4813,"has_fulltext":true,"cited_by_count":10,"citation_normalized_percentile":{"value":0.63828837,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"18","issue":"9","first_page":"1287","last_page":"1290"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9919999837875366},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.996999979019165},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.984000027179718},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.996999979019165},{"id":"https://openalex.org/keywords/irae-management","display_name":"irAE management","score":0.4230000078678131},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-related-pneumonitis","display_name":"immune-related pneumonitis","score":0.5789999961853027},{"id":"https://openalex.org/keywords/immune-mediated-colitis","display_name":"immune-related colitis","score":0.6639999747276306},{"id":"https://openalex.org/keywords/immune-related-endocrinopathy","display_name":"immune-related endocrinopathy","score":0.5680000185966492},{"id":"https://openalex.org/keywords/immune-related-hepatitis","display_name":"immune-related hepatitis","score":0.6010000109672546},{"id":"https://openalex.org/keywords/immune-related-skin-toxicity","display_name":"immune-related skin toxicity","score":0.41100001335144043},{"id":"https://openalex.org/keywords/immune-related-encephalitis","display_name":"immune-related encephalitis","score":0.5040000081062317},{"id":"https://openalex.org/keywords/immune-related-hypophysitis","display_name":"immune-related hypophysitis","score":0.5410000085830688}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9240380525588989},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7223880290985107},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6430541276931763},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.4918372631072998},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.42067721486091614},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3720387816429138},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3542550504207611},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2947390675544739},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.22945648431777954}],"mesh":[{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D016499","descriptor_name":"Radioimmunotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016499","descriptor_name":"Radioimmunotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016499","descriptor_name":"Radioimmunotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.6004/jnccn.2020.7640","doi":"https://doi.org/10.6004/jnccn.2020.7640","is_oa":true,"landing_page_url":"https://doi.org/10.6004/jnccn.2020.7640","pdf_url":"https://jnccn.org/downloadpdf/journals/jnccn/18/9/article-p1287.pdf","source":{"id":"https://openalex.org/S935620192","display_name":"Journal of the National Comprehensive Cancer Network","issn_l":"1540-1405","issn":["1540-1405","1540-1413"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4324004213","host_organization_name":"National Comprehensive Cancer","host_organization_lineage":["https://openalex.org/P4324004213"],"host_organization_lineage_names":["National Comprehensive Cancer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the National Comprehensive Cancer Network","raw_type":"journal-article"},{"id":"pmid:32886906","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32886906","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the National Comprehensive Cancer Network : JNCCN","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.6004/jnccn.2020.7640","doi":"https://doi.org/10.6004/jnccn.2020.7640","is_oa":true,"landing_page_url":"https://doi.org/10.6004/jnccn.2020.7640","pdf_url":"https://jnccn.org/downloadpdf/journals/jnccn/18/9/article-p1287.pdf","source":{"id":"https://openalex.org/S935620192","display_name":"Journal of the National Comprehensive Cancer Network","issn_l":"1540-1405","issn":["1540-1405","1540-1413"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4324004213","host_organization_name":"National Comprehensive Cancer","host_organization_lineage":["https://openalex.org/P4324004213"],"host_organization_lineage_names":["National Comprehensive Cancer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the National Comprehensive Cancer Network","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[{"id":"https://openalex.org/G8236929576","display_name":"Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC","funder_award_id":"K08CA245249","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320312570","display_name":"Jazz Pharmaceuticals","ror":"https://ror.org/055mhsv54"},{"id":"https://openalex.org/F4320313690","display_name":"Novocure","ror":"https://ror.org/018ec2p66"},{"id":"https://openalex.org/F4320317547","display_name":"Calithera Biosciences","ror":"https://ror.org/029gt5q28"},{"id":"https://openalex.org/F4320328062","display_name":"MorphoSys","ror":"https://ror.org/00ew7rg06"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3083367621.pdf","grobid_xml":"https://content.openalex.org/works/W3083367621.grobid-xml"},"referenced_works_count":30,"referenced_works":["https://openalex.org/W2104347254","https://openalex.org/W2156353875","https://openalex.org/W2293531514","https://openalex.org/W2466451466","https://openalex.org/W2527905628","https://openalex.org/W2567564314","https://openalex.org/W2625684877","https://openalex.org/W2673218446","https://openalex.org/W2743419024","https://openalex.org/W2753065806","https://openalex.org/W2771433910","https://openalex.org/W2786403629","https://openalex.org/W2786816161","https://openalex.org/W2796582438","https://openalex.org/W2807965874","https://openalex.org/W2888030212","https://openalex.org/W2891633409","https://openalex.org/W2899030278","https://openalex.org/W2903486314","https://openalex.org/W2905314444","https://openalex.org/W2913745075","https://openalex.org/W2917423789","https://openalex.org/W2917602796","https://openalex.org/W2924070172","https://openalex.org/W2947513934","https://openalex.org/W2985211404","https://openalex.org/W2988124258","https://openalex.org/W2996609538","https://openalex.org/W3021794875","https://openalex.org/W3083281449"],"related_works":["https://openalex.org/W2141197908","https://openalex.org/W4302292908","https://openalex.org/W3136661288","https://openalex.org/W2518309888","https://openalex.org/W3029766637","https://openalex.org/W3119950328","https://openalex.org/W3210090444","https://openalex.org/W2318567272","https://openalex.org/W2608267370","https://openalex.org/W3090649019"],"abstract_inverted_index":{"I":[0],"mmune":[1],"checkpoint":[2],"inhibitors":[3],"(ICIs)":[4],"have":[5,21,28,217,223,246],"revolutionized":[6],"the":[7,41,59,77,109,118,142,188,208,249,360,435,454],"treatment":[8,240,288,356,384],"of":[9,43,70,79,85,113,134,148,170,175,183,199,213,220,251,329,362,421],"ad-":[10],"vanced":[11],"malignancies,":[12],"including":[13],"non-small":[14],"cell":[15],"lung":[16],"cancer":[17],"(NSCLC).Although":[18],"these":[19,105,181,297],"agents":[20],"improved":[22,336,371],"clinical":[23,96,156],"outcomes":[24,157,321],"in":[25,58,82,150,197,296,338,359,457],"NSCLC,":[26],"they":[27,54],"also":[29,165],"led":[30],"to":[31,107,140,152,228,354,379,399,406,418],"unique":[32],"toxicities,":[33],"termed":[34],"immune-related":[35],"adverse":[36],"events":[37],"(irAEs).1-3":[38],"irAEs":[39,80,129,195,222,252,286,332,366],"are":[40,333,367,397,403,416],"result":[42],"nonspecific":[44],"immune":[45],"activation":[46],"and":[47,64,111,115,145,159,211,237,258,274,375,424,449],"can":[48],"affect":[49],"any":[50],"organ":[51],"system,":[52],"although":[53],"most":[55,404],"commonly":[56],"occur":[57],"skin,":[60],"liver,":[61],"gastrointestinal":[62],"tract,":[63],"endocrine":[65],"systems.4":[66],"In":[67,260],"this":[68,345,392],"issue":[69],"JNCCN,":[71],"Kichenadasse":[72,308],"et":[73,162,265,309],"al":[74,163,266,310],"5":[75,164,311],"evaluate":[76,141],"incidence":[78,110],"occurring":[81],"a":[83,261],"group":[84],"1,548":[86],"patients":[87,281,339,376,402,450],"with":[88,91,155,254,282,289,318,325,335,340,357,370,382,391],"NSCLC":[89,191,283,341],"treated":[90],"atezolizumab":[92,190],"monotherapy":[93],"on":[94,127,207,430],"4":[95,189],"trials.[6][7][8][9]":[97],"The":[98],"authors":[99],"used":[100],"individual":[101],"patient":[102,255],"data":[103],"from":[104,226],"trials":[106,192],"explore":[108],"timing":[112],"single-organ":[114,326],"multiorgan":[116,171,194,214,221,314,331,365,386],"irAEs,":[117,149,172,423],"latter":[119],"defined":[120],"as":[121],"either":[122],"concurrent":[123],"or":[124],"sequential":[125],"depending":[126],"whether":[128,330,353],"arose":[130],"within":[131],"7":[132],"days":[133],"one":[135],"another.The":[136],"primary":[137],"objectives":[138],"were":[139,278,323],"incidence,":[143],"grade,":[144],"time":[146],"course":[147],"addition":[151],"assessing":[153],"correlation":[154],"(overall":[158],"progression-free":[160,272],"survival).Kichenadasse":[161],"conducted":[166],"an":[167],"in-depth":[168],"evaluation":[169],"which":[173,401],"is":[174,185,205,342],"particular":[176],"interest":[177],"because":[178,344],"information":[179,204,346],"regarding":[180],"types":[182],"AEs":[184],"currently":[186],"sparse.Among":[187],"evaluated,":[193],"occurred":[196],"5.4%":[198],"patients.To":[200],"date,":[201],"very":[202,436],"little":[203],"available":[206,417],"frequency,":[209],"significance,":[210],"management":[212],"irAEs.Studies":[215],"that":[216,248,269,313],"reported":[218],"frequency":[219],"cited":[224],"incidences":[225],"5%":[227],"43%":[229],"across":[230],"multiple":[231],"tumor":[232],"types,":[233],"encompassing":[234],"both":[235],"single-agent":[236],"multiagent":[238],"ICI":[239,383,452],"modalities.[10][11][12][13][14][15][16][17][18]":[241],"Interestingly,":[242],"previously":[243],"published":[244],"reports":[245],"shown":[247],"development":[250,420],"correlates":[253],"response":[256,276],"rate":[257],"survival.19,20":[259],"2019":[262],"study,":[263],"Cortellini":[264],"12":[267],"found":[268,312],"overall":[270],"survival,":[271,273],"objective":[275],"rates":[277],"higher":[279],"among":[280],"who":[284],"experienced":[285],"during":[287,451],"anti-PD-1":[290],"agents;":[291],"however,":[292,412],"no":[293,413],"significant":[294],"difference":[295],"endpoints":[298],"was":[299,316],"observed":[300,324],"when":[301,388],"comparing":[302],"single-site":[303],"versus":[304],"multiple-site":[305],"irAEs.In":[306],"contrast,":[307],"involvement":[315],"associated":[317,334,369],"better":[319],"survival":[320,337,372],"than":[322],"involvement.The":[327],"question":[328],"important":[343],"could":[347],"potentially":[348],"help":[349],"guide":[350],"decisions":[351],"about":[352],"continue":[355],"ICIs":[358],"face":[361],"treatment-related":[363],"toxicity.If":[364],"truly":[368],"outcomes,":[373],"clinicians":[374,448],"may":[377],"choose":[378],"forge":[380],"ahead":[381],"despite":[385],"toxicity,":[387],"possible.To":[389],"assist":[390],"critical":[393],"decision,":[394],"effective":[395],"tools":[396,415,440],"needed":[398],"predict":[400,419],"likely":[405],"experience":[407],"serious":[408],"and/or":[409],"fatal":[410],"toxicities.Currently,":[411],"refined":[414],"ICI-induced":[422],"surveillance":[425],"for":[426,443,461],"occurrence":[427],"generally":[428],"relies":[429],"traditional":[431],"laboratory":[432],"markers.21":[433],"At":[434],"least,":[437],"developing":[438],"predictive":[439],"would":[441],"allow":[442],"more":[444],"relevant":[445],"discussion":[446],"between":[447],"therapy.Given":[453],"dramatic":[455],"improvement":[456],"See":[458],"page":[459],"1191":[460],"related":[462],"article.":[463]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-15T10:00:46.086208","created_date":"2025-10-10T00:00:00"}